Powered by Business Wire
Search Results for Topix.net

J-Plasma® Recognized as an Innovation of the Year by The Society of Laparoendoscopic Surgeons

CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical (NYSE: BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced that J-Plasma® has been recognized as an Innovation of the Year by The Society of Laparoendoscopic Surgeons (SLS).

“We are honored that J-Plasma® has been recognized as an Innovation of the Year by The Society of Laparoendoscopic Surgeons. This prestigious recognition is further evidence of the technological advantages of J-Plasma® and its usefulness to surgeons across a number of different minimally-invasive procedures”

SLS is an educational, non-profit organization established to ensure the highest standards for the practice of laparoscopic, endoscopic and minimally invasive surgery. Each year, SLS recognizes the most innovative products of the last 12 months that have a broad application in minimally invasive surgery. J-Plasma® is one of 7 products to receive this recognition in 2014.

Bovie Medical will receive the recognition at the opening ceremony of SLS’ Minimally Invasive Surgery Week Annual Meeting and Endo Expo on Wednesday, September 10, 2014, in Las Vegas.

“We are honored that J-Plasma® has been recognized as an Innovation of the Year by The Society of Laparoendoscopic Surgeons. This prestigious recognition is further evidence of the technological advantages of J-Plasma® and its usefulness to surgeons across a number of different minimally-invasive procedures,” said Robert L. Gershon, Chief Executive Officer of Bovie Medical.

J-Plasma® is a plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

About SLS

The Society of Laparoendoscopic Surgeons was established as an educational, non-profit organization to help ensure the highest standards for the practice of laparoscopic, endoscopic and minimally invasive surgery. The Society serves surgeons from various specialties and other health professionals who are interested in advancing their expertise in the diagnostic and therapeutic uses of Laparoendoscopic and minimally invasive surgical techniques. With an international membership of over 6,000 surgeons, the organization offers a unique approach to the study and education of minimally invasive surgery by bringing together different medical specialties that use the techniques and tools of minimally invasive surgery.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s reports on Forms 10-K/A and 10-Qs for the year ended December 31, 2013 and the quarters ended March 31, 2014, and June 30, 2014, respectively. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:
MBS Value Partners
Lynn Morgen and Hugh Collins
212-750-5800
Investor.relations@boviemed.com